Related Experiment Videos
VM-26 in colorectal carcinoma: a Southwest Oncology Group study
N Oishi1, T R Fleming, L Laufman
1Cancer Research Center of Hawaii.
Investigational New Drugs
|February 1, 1990
Abstract:
In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.